ShareChat
click to see wallet page
search
#🦠भारत में निपाह वायरस से पहली मौत 😲
🦠भारत में निपाह वायरस से पहली मौत 😲 - from respiratory infection symptoms to encephalitis (brain swelling) leading to coma or death: An estimated 40 to 75 percent of people infected with Nipah virus die: Although MOST CASES ARE TRANSMITTED VIA ANIMALS, person-to-person transmission can occur Currently there is no licensed vaccine or treatment for Nipah virus infection 'Nipah virus poses a considerable pandemic threat because it mutates relatively easily causes disease in a wide range of mammals can transmit from large person-to-person; and kills a percentage of the people it infects;" said NIAID DIRECTOR ANTHONY S. FAUCI M.D. "The need for a preventive Nipah virus vaccine is significant " 00 NIAIDs PANDEMIC PREPAREDNESS PLAN published earlier this year; established a framework to study viruses of pandemic potential and prioritize research on prototype pathogens such as Nipah virus using ' This is the first clinical trial the prototype pathogen approach since the plans publication THE EXPERIMENTAL MRNA-1215 NPAH VIRUS VACCINE will be tested in a dose-escalation clinical trial to evaluate its safety tolerability and ability to generate an immune response in 40 healthy adults ages १८ to 6० vears. Specifically 4 aroups of १० from respiratory infection symptoms to encephalitis (brain swelling) leading to coma or death: An estimated 40 to 75 percent of people infected with Nipah virus die: Although MOST CASES ARE TRANSMITTED VIA ANIMALS, person-to-person transmission can occur Currently there is no licensed vaccine or treatment for Nipah virus infection 'Nipah virus poses a considerable pandemic threat because it mutates relatively easily causes disease in a wide range of mammals can transmit from large person-to-person; and kills a percentage of the people it infects;" said NIAID DIRECTOR ANTHONY S. FAUCI M.D. "The need for a preventive Nipah virus vaccine is significant " 00 NIAIDs PANDEMIC PREPAREDNESS PLAN published earlier this year; established a framework to study viruses of pandemic potential and prioritize research on prototype pathogens such as Nipah virus using ' This is the first clinical trial the prototype pathogen approach since the plans publication THE EXPERIMENTAL MRNA-1215 NPAH VIRUS VACCINE will be tested in a dose-escalation clinical trial to evaluate its safety tolerability and ability to generate an immune response in 40 healthy adults ages १८ to 6० vears. Specifically 4 aroups of १० - ShareChat